001     130418
005     20240228143431.0
024 7 _ |a 10.1007/s00401-016-1549-x
|2 doi
024 7 _ |a pmid:26920151
|2 pmid
024 7 _ |a pmc:PMC5039033
|2 pmc
024 7 _ |a 0001-6322
|2 ISSN
024 7 _ |a 1432-0533
|2 ISSN
024 7 _ |a altmetric:6015717
|2 altmetric
037 _ _ |a DKFZ-2017-05497
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Rivera, Barbara
|b 0
245 _ _ |a Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors.
260 _ _ |a Berlin
|c 2016
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1522138933_18537
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Dysembryoplastic neuroepithelial tumor (DNET) is a benign brain tumor associated with intractable drug-resistant epilepsy. In order to identify underlying genetic alterations and molecular mechanisms, we examined three family members affected by multinodular DNETs as well as 100 sporadic tumors from 96 patients, which had been referred to us as DNETs. We performed whole-exome sequencing on 46 tumors and targeted sequencing for hotspot FGFR1 mutations and BRAF p.V600E was used on the remaining samples. FISH, copy number variation assays and Sanger sequencing were used to validate the findings. By whole-exome sequencing of the familial cases, we identified a novel germline FGFR1 mutation, p.R661P. Somatic activating FGFR1 mutations (p.N546K or p.K656E) were observed in the tumor samples and further evidence for functional relevance was obtained by in silico modeling. The FGFR1 p.K656E mutation was confirmed to be in cis with the germline p.R661P variant. In 43 sporadic cases, in which the diagnosis of DNET could be confirmed on central blinded neuropathology review, FGFR1 alterations were also frequent and mainly comprised intragenic tyrosine kinase FGFR1 duplication and multiple mutants in cis (25/43; 58.1 %) while BRAF p.V600E alterations were absent (0/43). In contrast, in 53 cases, in which the diagnosis of DNET was not confirmed, FGFR1 alterations were less common (10/53; 19 %; p < 0.0001) and hotspot BRAF p.V600E (12/53; 22.6 %) (p < 0.001) prevailed. We observed overexpression of phospho-ERK in FGFR1 p.R661P and p.N546K mutant expressing HEK293 cells as well as FGFR1 mutated tumor samples, supporting enhanced MAP kinase pathway activation under these conditions. In conclusion, constitutional and somatic FGFR1 alterations and MAP kinase pathway activation are key events in the pathogenesis of DNET. These findings point the way towards existing targeted therapies.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a FGFR1 protein, human
|0 EC 2.7.10.1
|2 NLM Chemicals
650 _ 7 |a Receptor, Fibroblast Growth Factor, Type 1
|0 EC 2.7.10.1
|2 NLM Chemicals
650 _ 7 |a Proto-Oncogene Proteins B-raf
|0 EC 2.7.11.1
|2 NLM Chemicals
700 1 _ |a Gayden, Tenzin
|b 1
700 1 _ |a Carrot-Zhang, Jian
|b 2
700 1 _ |a Nadaf, Javad
|b 3
700 1 _ |a Boshari, Talia
|b 4
700 1 _ |a Faury, Damien
|b 5
700 1 _ |a Zeinieh, Michele
|b 6
700 1 _ |a Blanc, Romeo
|b 7
700 1 _ |a Burk, David L
|b 8
700 1 _ |a Fahiminiya, Somayyeh
|b 9
700 1 _ |a Bareke, Eric
|b 10
700 1 _ |a Schüller, Ulrich
|b 11
700 1 _ |a Monoranu, Camelia M
|b 12
700 1 _ |a Sträter, Ronald
|b 13
700 1 _ |a Kerl, Kornelius
|b 14
700 1 _ |a Niederstadt, Thomas
|b 15
700 1 _ |a Kurlemann, Gerhard
|b 16
700 1 _ |a Ellezam, Benjamin
|b 17
700 1 _ |a Michalak, Zuzanna
|b 18
700 1 _ |a Thom, Maria
|b 19
700 1 _ |a Lockhart, Paul J
|b 20
700 1 _ |a Leventer, Richard J
|b 21
700 1 _ |a Ohm, Milou
|b 22
700 1 _ |a MacGregor, Duncan
|b 23
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 24
|u dkfz
700 1 _ |a Karamchandani, Jason
|b 25
700 1 _ |a Greenwood, Celia M T
|b 26
700 1 _ |a Berghuis, Albert M
|b 27
700 1 _ |a Bens, Susanne
|b 28
700 1 _ |a Siebert, Reiner
|b 29
700 1 _ |a Zakrzewska, Magdalena
|b 30
700 1 _ |a Liberski, Pawel P
|b 31
700 1 _ |a Zakrzewski, Krzysztof
|b 32
700 1 _ |a Sisodiya, Sanjay M
|b 33
700 1 _ |a Paulus, Werner
|b 34
700 1 _ |a Albrecht, Steffen
|b 35
700 1 _ |a Hasselblatt, Martin
|b 36
700 1 _ |a Jabado, Nada
|b 37
700 1 _ |a Foulkes, William D
|b 38
700 1 _ |a Majewski, Jacek
|b 39
773 _ _ |a 10.1007/s00401-016-1549-x
|g Vol. 131, no. 6, p. 847 - 863
|0 PERI:(DE-600)1458410-4
|n 6
|p 847 - 863
|t Acta neuropathologica
|v 131
|y 2016
|x 1432-0533
909 C O |o oai:inrepo02.dkfz.de:130418
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)551bb92841f634070997aa168d818492
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2016
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ACTA NEUROPATHOL : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21